Intercept rises after adjusting Phase III NASH study

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) added $5.82 to $118.51 on Friday after making changes to its Phase III REGENERATE trial of Ocaliva obeticholic acid to treat non-alcoholic steatohepatitis in patients with liver fibrosis. The trial will now require Ocaliva to meet only one of two co-primary endpoints.

On a conference call, President and CEO Mark Pruzanski said that by making the changes, the company has "lowered the hurdle for a successful trial."...